Sebastian Møller Nguyen Heimbürger

Dr. Sebastian Møller Nguyen Heimbürger

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Peptides
Verified
Journal Article
Closed access
SHSebastian Møller Nguyen Heimbürger
Sebastian Møller Nguyen Heimbürger
NBNatasha C. Bergmann
Natasha C. Bergmann
RARobert Augustin
Robert Augustin
LGLærke S. Gasbjerg
Lærke S. Gasbjerg
MCMikkel B. Christensen
Mikkel B. Christensen
FKFilip Knop
Filip Knop

16 January 2020 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
NBNatasha C. Bergmann
Natasha C. Bergmann
LGLærke S. Gasbjerg
Lærke S. Gasbjerg
SHSebastian Møller Nguyen Heimbürger
Sebastian Møller Nguyen Heimbürger
LKLiva S.L. Krogh
Liva S.L. Krogh
FDFlemming Dela
Flemming Dela
FKFilip Knop
Filip Knop
OBJECTIVE Dual incretin receptor agonists in clinical development have shown reductions in body weight and hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the impact of glucose-dependent insulinotropic polypeptide (GIP) receptor activation remains unclear. Here, we evaluated the effects of high-dose exogenous GIP on energy intake, energy expenditure, plasma glucose, and glucose-regulating hormones in patients with type 2 diabetes treated with a long-acting glucagon-like peptide 1 receptor (GLP-1R) agonist. RESEARCH DESIGN AND METHODS In a randomized, double-blind design, men with type 2 diabetes (n = 22, mean ± SEM HbA1c 6.8 ± 0.1% [51 ± 1.5 mmol/mol]) treated with metformin and long-acting GLP-1R agonists were subjected to two 5-h continuous infusions (separated by a washout period of ≥3 days): one with GIP (6 pmol/kg/min) and another with saline (placebo). After 60 min of infusion, a liquid mixed-meal test was performed, and after 270 min of infusion, an ad libitum meal was served for evaluation of energy intake (primary end point). RESULTS Energy intake was similar during GIP and placebo infusion (648 ± 74 kcal vs. 594 ± 55 kcal, respectively; P = 0.480), as were appetite measures and energy expenditure. Plasma glucagon and glucose were higher during GIP infusion compared with placebo infusion (P = 0.026 and P = 0.017) as assessed by area under the curve. CONCLUSIONS In patients with type 2 diabetes, GIP infusion on top of treatment with metformin and a long-acting GLP-1R agonist did not affect energy intake, appetite, or energy expenditure but increased plasma glucose compared with placebo. These results indicate no acute beneficial effects of combining GIP and GLP-1.

16 September 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
SHSebastian Møller Nguyen Heimbürger
Sebastian Møller Nguyen Heimbürger
BHBjørn Hoe
Bjørn Hoe
CNChris Neumann Nielsen
Chris Neumann Nielsen
NBNatasha Bergmann
Natasha Bergmann
KSKirsa Skov-Jeppesen
Kirsa Skov-Jeppesen
FKFilip Knop
Filip Knop
Context Glucose-dependent insulinotropic polypeptide (GIP) has been proposed to exert insulin-independent effects on lipid and bone metabolism. Objective We investigated the effects of a 6-day subcutaneous GIP infusion on circulating lipids, white adipose tissue (WAT), brown adipose tissue (BAT), hepatic fat content, inflammatory markers, respiratory exchange ratio (RER), and bone homeostasis in patients with type 1 diabetes. Methods In a randomized, placebo-controlled, double-blind, crossover study, 20 men with type 1 diabetes underwent a 6-day continuous subcutaneous infusion with GIP (6 pmol/kg/min) and placebo (saline), with an interposed 7-day washout period. Results During GIP infusion, participants (26 ± 8 years [mean ± SD]; BMI 23.8 ± 1.8 kg/m2; glycated hemoglobin A1c 51 ± 10 mmol/mol [6.8 ± 3.1%]) experienced transiently increased circulating concentrations of nonesterified fatty acid (NEFA) (P = 0.0005), decreased RER (P = 0.009), indication of increased fatty acid β-oxidation, and decreased levels of the bone resorption marker C-terminal telopeptide (P = 0.000072) compared with placebo. After 6 days of GIP infusion, hepatic fat content was increased by 12.6% (P = 0.007) and supraclavicular skin temperature, a surrogate indicator of BAT activity, was increased by 0.29 °C (P < 0.000001) compared with placebo infusion. WAT transcriptomic profile as well as circulating lipid species, proteome, markers of inflammation, and bone homeostasis were unaffected. Conclusion Six days of subcutaneous GIP infusion in men with type 1 diabetes transiently decreased bone resorption and increased NEFA and β-oxidation. Further, hepatic fat content, and supraclavicular skin temperature were increased without affecting WAT transcriptomics, the circulating proteome, lipids, or inflammatory markers.

1 March 2020 in Peptides
Verified
Journal Article
Closed access
MCMikkel B. Christensen
Mikkel B. Christensen
LGLærke S. Gasbjerg
Lærke S. Gasbjerg
SHSebastian Møller Nguyen Heimbürger
Sebastian Møller Nguyen Heimbürger
SSSigne Stensen
Signe Stensen
Tina VilsbøllTina Vilsbøll
Tina Vilsbøll
FKFilip Knop
Filip Knop

7 February 2019 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
SHSebastian Møller Nguyen Heimbürger
Sebastian Møller Nguyen Heimbürger
ABAndreas Brønden
Andreas Brønden
NJNicklas J. Johansen
Nicklas J. Johansen
TDThomas F. Dejgaard
Thomas F. Dejgaard
TVTina Vilsbøll
Tina Vilsbøll
FKFilip Knop
Filip Knop
Exenatide once weekly (QW) is a glucagon-like peptide 1 receptor agonist (GLP-1RA) that was approved in 2012 in Europe and the U.S.A. for the treatment of type 2 diabetes (T2D). Areas covered: This review provides an overview of the safety and efficacy of exenatide QW for the treatment of T2D and evaluates the benefit-risk ratio compared to other available long-acting GLP-1RAs. In addition, the authors provide an outline of the novel formulations and delivery methods of exenatide. Expert opinion: Exenatide QW is an efficacious and safe treatment for T2D. However, head-to-head trials have demonstrated exenatide QW to be inferior to liraglutide and semaglutide with respect to effects on fasting plasma glucose, glycated hemoglobin A1c, and bodyweight. In addition, exenatide QW appears inferior to liraglutide and semaglutide in terms of cardiovascular risk reduction. Currently, the overall risk-benefit profiles for the range of GLP-1RAs point to liraglutide and semaglutide as first-choice for the management of T2D, which has been confirmed by a recently published consensus report on the treatment of T2D from the American Diabetes Association and the European Association for the Study of Diabetes. The pricing of exenatide QW will most likely be a key determinant for its place in the future management of T2D.

17 August 2021 in Diabetologia
Verified
Journal Article
Closed access
PDF file
SHSebastian Møller Nguyen Heimbürger
Sebastian Møller Nguyen Heimbürger
BHBjørn Hoe
Bjørn Hoe
CNChris N. Nielsen
Chris N. Nielsen
NBNatasha Bergmann
Natasha Bergmann
BHBolette Hartmann
Bolette Hartmann
FKFilip Knop
Filip Knop